- Home
- FEMY vs PULM Comparison
FEMY vs PULM Comparison
Compare FEMY & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- PULM
- Stock Information
- Founded
- FEMY 2004
- PULM 2003
- Country
- FEMY United States
- PULM United States
- Employees
- FEMY N/A
- PULM N/A
- Industry
- FEMY Medical/Dental Instruments
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- PULM Health Care
- Exchange
- FEMY Nasdaq
- PULM Nasdaq
- Market Cap
- FEMY 29.9M
- PULM 20.5M
- IPO Year
- FEMY 2021
- PULM N/A
- Fundamental
- Price
- FEMY $0.83
- PULM $5.57
- Analyst Decision
- FEMY Strong Buy
- PULM
- Analyst Count
- FEMY 3
- PULM 0
- Target Price
- FEMY $8.67
- PULM N/A
- AVG Volume (30 Days)
- FEMY 151.8K
- PULM 10.9K
- Earning Date
- FEMY 08-07-2025
- PULM 08-12-2025
- Dividend Yield
- FEMY N/A
- PULM N/A
- EPS Growth
- FEMY N/A
- PULM N/A
- EPS
- FEMY N/A
- PULM N/A
- Revenue
- FEMY $1,699,232.00
- PULM $1,921,000.00
- Revenue This Year
- FEMY $283.83
- PULM N/A
- Revenue Next Year
- FEMY $161.03
- PULM $134.88
- P/E Ratio
- FEMY N/A
- PULM N/A
- Revenue Growth
- FEMY 61.97
- PULM N/A
- 52 Week Low
- FEMY $0.69
- PULM $1.78
- 52 Week High
- FEMY $1.80
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- FEMY 36.62
- PULM 36.25
- Support Level
- FEMY $0.91
- PULM $5.20
- Resistance Level
- FEMY $0.93
- PULM $6.15
- Average True Range (ATR)
- FEMY 0.04
- PULM 0.30
- MACD
- FEMY -0.01
- PULM -0.05
- Stochastic Oscillator
- FEMY 0.00
- PULM 22.70
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).